PTH
Invesco Dorsey Wright Healthcare Momentum ETF
The Invesco DWA Healthcare Momentum Portfolio tracks an index of U.S. healthcare firms selected and weighted by price momentum.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 122.1 M
ASSETS UNDER MGMT
60 bp
EXPENSES
Fund Basics
| Inception date | Oct 12, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| MEDPACE HOLDINGS, INC. | 4.9 % |
| INSMED INC | 4.6 % |
| NEKTAR THERAPEUTICS | 4.2 % |
| HIMS & HERS HEALTH, INC. CLASS A | 4.2 % |
| TENET HEALTHCARE CORP | 3.8 % |
| BOSTON SCIENTIFIC CORP | 3.7 % |
| CIDARA THERAPEUTICS INC | 3.5 % |
| NATERA INC | 3.2 % |
| GUARDANT HEALTH, INC. | 3.1 % |
| ALNYLAM PHARMACEUTICALS INC | 2.9 % |
Constituent Breakdown
| Number of holdings | 48 |
| Herfindahl-Hirschman Index | 247 |
| Wgt avg mkt cap (mns) | $14,824 |
| Large cap (>$10bn) | 38.2% |
| Mid cap ($2-10bn) | 33.6% |
| Small cap (<$2bn) | 14.6% |
| Developed mkts. | 86.4% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.0 % |
 |
NETHERLANDS | 1.4 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 1.8% | 26.1% | 11.7% | 8.2% | -0.6% | 13.1% | -- | 9.7% |
| Dividend Yield | 0.0% | 3.8% | 1.7% | 1.1% | 0.6% | 0.3% | -- | 0.3% |
| Total Returns | 1.8% | 29.9% | 13.5% | 9.3% | 0.0% | 13.5% | -- | 10.0% | Ann. Volatility | 25.9% | 23.1% | 24.9% | 24.8% | 25.4% | 27.1% | -- | 24.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.01 | 30% |
| MSCI EAFE | 0.80 | 25% |
| MSCI Emg Mkts | 0.54 | 19% |
Liquidity Measures
| Avg. volume (000) | 11 |
| ADV traded (mns) | $1 |
| Turnover | 0.5% |
| Avg. Bid/Ask (% of price) | 0.27% |
Technical Indicators
| 30d moving avg. (EMA) | $50.68 |
| Relative strength (RSI) | 51 |
| MACD/Signal | 0.41/0.78 |
| Bollinger Bands (Upper/Lower) | $54.17/$48.95 |
| Short interest (% of AUM) | 0.7% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PTH |
Expenses vs. PTH |
ALTAR Score™ vs. PTH |
|---|---|---|---|---|
| HELX | Franklin Genomic Advancements ETF | 30.0% | -10 bp | +0.2% |
| XBI | State Street SPDR S&P Biotech ETF | 20.7% | -25 bp | +1.2% |
| BBP | Virtus LifeSci Biotech Products ETF | 18.9% | +19 bp | -2.5% |
| IBB | iShares Biotechnology ETF | 17.1% | -15 bp | +0.7% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 16.7% | -41 bp | +1.5% |
| FMED | Fidelity Disruptive Medicine ETF | 15.8% | -10 bp | 0.0% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 14.9% | +15 bp | +2.7% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 14.7% | +5 bp | +2.5% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 13.8% | +8 bp | +3.7% |
| GNOM | Global X Genomics & Biotechnology ETF | 13.3% | -10 bp | -2.0% |
Risk and Returns: PTH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/6/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.2%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,207 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. PTH's ALTAR Score™ is approximately -3.2 standard
deviations above the category average. This places PTH in the 1st percentile
among funds in the category.
Sell-Side Consensus
$69.89
PRICE TARGET
+34.7%
UPSIDE